Ayala Pharmaceuticals Announces $25 Million Strategic Financing

Funding Extends Cash Runway through Multiple Expected Value Drivers Into 2023

Funds Expected to Support the Recently Announced Accelerated Development of AL102 for the Treatment of Desmoid Tumors into Pivotal Phase 2/3 Study

Recent Posts

October 16, 2024 Exclusive Agreement Includes $18 Million in Milestone Payments to Orasis, Together with a Double-Digit Royalty on Sales...

October 29, 2024 MENLO PARK, Calif.–( BUSINESS WIRE )–Secret Double Octopus, the market leader in workforce passwordless authentication,...

ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002...